Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in Oncologist Retrieve available abstracts of 73 articles: HTML format

Single Articles

March 2023
1. ZHANG J, Johnson M, Barve M, Bazhenova L, et al
   Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
   Oncologist. 2023 Mar 9:oyad051. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2023
2. NOVELLO S, Califano R, Reinmuth N, Tamma A, et al
   RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
   Oncologist. 2023 Feb 23:oyac264. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. 
   Correction to: Management of Lung Cancer in the Patient with Interstitial Lung Disease.
   Oncologist. 2023 Feb 9:oyad018. doi: 10.1093.
   PubMed    
   
   
   December 2022
4. BARLESI F, Isambert N, Felip E, Cho BC, et al
   Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
   Oncologist. 2022 Dec 26:oyac253. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. WOODFORD K, Koo K, Reynolds J, Stirling RG, et al
   Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis.
   Oncologist. 2022 Dec 20:oyac246. doi: 10.1093.
   PubMed     Abstract available
   
   
   November 2022
6. FRANK AJ, Dagogo-Jack I, Dobre IA, Tait S, et al
   Management of Lung Cancer in the Patient with Interstitial Lung Disease.
   Oncologist. 2022 Nov 25:oyac226. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. CHIHARA Y, Takeda T, Goto Y, Nakamura Y, et al
   A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
   Oncologist. 2022;27:903-e834.
   PubMed     Abstract available
   
   
   
8. YAO J, Bergsland E, Aggarwal R, Aparicio A, et al
   DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
   Oncologist. 2022;27:940-951.
   PubMed     Abstract available
   
   
   October 2022
9. 
   Expression of Concern: Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
   Oncologist. 2022 Oct 31. pii: 6782256. doi: 10.1093.
   PubMed    
   
   
   
10. MOHAMED L, Manjrekar S, Ng DP, Walsh A, et al
    The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs.
    Oncologist. 2022;27:849-856.
    PubMed     Abstract available
    
    
    September 2022
11. ALVES PINTO I, de Oliveira Cavagna R, Virginio da Silva AL, Dias JM, et al
    EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.
    Oncologist. 2022 Sep 13. pii: 6696863. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al
    Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study.
    Oncologist. 2022 Sep 6. pii: 6693237. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. FUJIWARA Y, Takahashi Y, Okada M, Kishimoto T, et al
    Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
    Oncologist. 2022;27:e703-e722.
    PubMed     Abstract available
    
    
    August 2022
14. HSU ML, Murray JC, Psoter KJ, Zhang J, et al
    Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
    Oncologist. 2022 Aug 16. pii: 6668266. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. 
    Correction to: Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
    Oncologist. 2022 Aug 6. pii: 6657714. doi: 10.1093.
    PubMed    
    
    
    
16. OFFIN M, Rusch VW, Rimner A, Adusumilli PS, et al
    Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice.
    Oncologist. 2022;27:610-614.
    PubMed    
    
    
    July 2022
17. SAKURADA T, Nokihara H, Koga T, Zamami Y, et al
    Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.
    Oncologist. 2022;27:e554-e560.
    PubMed     Abstract available
    
    
    
18. WANG J, Martin-Romano P, Cassier P, Johnson M, et al
    Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.
    Oncologist. 2022;27:536-e553.
    PubMed     Abstract available
    
    
    
19. JAHANZEB M, Lin HM, Wu Y, Zhang P, et al
    Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Oncologist. 2022 Jul 4. pii: 6628677. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
20. IKEDA S, Kato T, Kenmotsu H, Ogura T, et al
    Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
    Oncologist. 2022 Jun 27. pii: 6618634. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. MACK PC, Klein MI, Ayers KL, Zhou X, et al
    Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Oncologist. 2022;27:476-486.
    PubMed     Abstract available
    
    
    
22. GANTZER J, Davidson G, Vokshi B, Weingertner N, et al
    Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:501-511.
    PubMed     Abstract available
    
    
    May 2022
23. HUANG RSP, Harries L, Decker B, Hiemenz MC, et al
    Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Oncologist. 2022 May 22. pii: 6590419. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. MURUGESAN K, Jin DX, Comment LA, Fabrizio D, et al
    Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
    Oncologist. 2022 May 22. pii: 6590420. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. ISAWA T, Toi Y, Sugawara S, Taguri M, et al
    Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:e410-e419.
    PubMed     Abstract available
    
    
    April 2022
26. PASELLO G, Lorenzi M, Calvetti L, Oliani C, et al
    Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
    Oncologist. 2022 Apr 16. pii: 6569250. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. POPAT S, Hsia TC, Hung JY, Jung HA, et al
    Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Oncologist. 2022;27:255-265.
    PubMed     Abstract available
    
    
    March 2022
28. LEMMON CA, Zabor EC, Pennell NA
    Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
    Oncologist. 2022 Mar 14. pii: 6548144. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. JIAN H, Wang K, Cheng Y, Ding L, et al
    Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2022;27:163-e213.
    PubMed     Abstract available
    
    
    
30. TAN R, Yun C, Seetasith A, Sheinson D, et al
    Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.
    Oncologist. 2022;27:236-243.
    PubMed     Abstract available
    
    
    
31. WELLS JC, Sidhu A, Ding K, Smoragiewicz M, et al
    Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
    Oncologist. 2022;27:e286-e293.
    PubMed     Abstract available
    
    
    
32. STURGILL EG, Misch A, Jones CC, Luckett D, et al
    Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
    Oncologist. 2022;27:175-182.
    PubMed     Abstract available
    
    
    
33. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2022;27:87-e115.
    PubMed     Abstract available
    
    
    
34. PENG W, Cao L, Chen L, Lin G, et al
    Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Oncologist. 2022;27:e116-e125.
    PubMed     Abstract available
    
    
    
35. PAVAN A, Ferro A, Fortarezza F, Schiavon M, et al
    Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
    Oncologist. 2022;27:e199-e202.
    PubMed     Abstract available
    
    
    February 2022
36. MORABITO A, Manzo A, Montanino A, Rachiglio AM, et al
    Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.
    Oncologist. 2022;27:7-12.
    PubMed     Abstract available
    
    
    
37. MOSKOVITZ M, Dudnik E, Shamai S, Rotenberg Y, et al
    ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
    Oncologist. 2022;27:e76-e84.
    PubMed     Abstract available
    
    
    
38. MIKKELSEN MK, Lund CM, Vinther A, Tolver A, et al
    Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial.
    Oncologist. 2022;27:67-78.
    PubMed     Abstract available
    
    
    December 2021
39. LI J, Wang Q, Ge J, Tian Y, et al
    BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Oncologist. 2021;26:e2115-e2119.
    PubMed     Abstract available
    
    
    
40. ARRIETA O, Lara-Mejia L, Bautista-GonzAlez E, Heredia D, et al
    Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies.
    Oncologist. 2021;26:1035-1043.
    PubMed     Abstract available
    
    
    
41. OZA AM, Dubois F, Hegg R, Hernandez CA, et al
    A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
    Oncologist. 2021;26:e2254-e2264.
    PubMed     Abstract available
    
    
    November 2021
42. PETRILLO LA, Zhou AZ, Sullivan R, Volandes A, et al
    Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.
    Oncologist. 2021;26:e2090-e2093.
    PubMed     Abstract available
    
    
    
43. AMELOT A
    Regarding "Surgical Metastasectomy in the Spine: A Review Article".
    Oncologist. 2021;26:e2097.
    PubMed    
    
    
    
44. ZHANG G, Xia P, Zhao S, Yuan L, et al
    Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification.
    Oncologist. 2021;26:e1898-e1902.
    PubMed     Abstract available
    
    
    October 2021
45. OSPINA AV, Bruges R, Mantilla W, Triana I, et al
    Impact of COVID-19 Infection on Patients with Cancer: Experience in a Latin American Country: The ACHOCC-19 Study.
    Oncologist. 2021;26:e1761-e1773.
    PubMed     Abstract available
    
    
    
46. CHEN X, Sheikh K, Nakajima E, Lin CT, et al
    Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Oncologist. 2021;26:e1822-e1832.
    PubMed     Abstract available
    
    
    
47. GAN HK, Millward M, Jalving M, Garrido-Laguna I, et al
    A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
    Oncologist. 2021;26:e1844-e1853.
    PubMed     Abstract available
    
    
    September 2021
48. MINCHOM A, Tan AC, Massarelli E, Subbiah V, et al
    Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial.
    Oncologist. 2021 Sep 15. doi: 10.1002/onco.13976.
    PubMed     Abstract available
    
    
    
49. ARAI D, Sato T, Nakachi I, Fujisawa D, et al
    Longitudinal Assessment of Prognostic Understanding in Advanced Lung Cancer Patients and Its Association with Their Psychological Distress.
    Oncologist. 2021 Sep 12. doi: 10.1002/onco.13973.
    PubMed     Abstract available
    
    
    
50. GOSSLING GCL, Chedid MF, Pereira FS, da Silva RK, et al
    Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience.
    Oncologist. 2021;26:e1581-e1588.
    PubMed     Abstract available
    
    
    August 2021
51. LIN S, Luo S, Gu D, Li M, et al
    First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a United States-based cost-effectiveness analysis.
    Oncologist. 2021 Aug 25. doi: 10.1002/onco.13954.
    PubMed     Abstract available
    
    
    
52. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2021 Aug 23. doi: 10.1002/onco.13951.
    PubMed     Abstract available
    
    
    
53. XIANG M, Yang X, Ren S, Du F, et al
    Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
    Oncologist. 2021 Aug 22. doi: 10.1002/onco.13950.
    PubMed     Abstract available
    
    
    July 2021
54. IVANOVIC M, Knez L, Herzog A, Kovacevic M, et al
    Immunotherapy for metastatic non-small cell lung cancer: Real-world data from an academic Central and Eastern European centre.
    Oncologist. 2021 Jul 19. doi: 10.1002/onco.13909.
    PubMed     Abstract available
    
    
    
55. LEE Y, Cho Y, Park EY, Park SY, et al
    One-step polymerase chain reaction-free nanowire-based plasma cell-free DNA assay to detect EML4-ALK fusion and to monitor resistance in lung cancer.
    Oncologist. 2021 Jul 17. doi: 10.1002/onco.13902.
    PubMed     Abstract available
    
    
    
56. TJONG MC, Doherty M, Tan H, Chan WC, et al
    Province-Wide Analysis of Patient Reported Outcomes for Stage IV Non-Small Cell Lung Cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13890.
    PubMed     Abstract available
    
    
    
57. GRAY J, Thompson JC, Carpenter EL, Elkhouly E, et al
    Plasma cell-free DNA genotyping-from an emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13889.
    PubMed     Abstract available
    
    
    
58. GEORGE S, Bell EJ, Zheng Y, Kim R, et al
    The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    Oncologist. 2021;26:e1205-e1215.
    PubMed     Abstract available
    
    
    
59. AYERS KL, Mullaney T, Zhou X, Liu JJ, et al
    Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
    Oncologist. 2021;26:e1226-e1239.
    PubMed     Abstract available
    
    
    June 2021
60. LOI M, Alifano M, Scorsetti M, Nuyttens JJ, et al
    Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer.
    Oncologist. 2021;26:e1085-e1086.
    PubMed    
    
    
    
61. VARLOTTO JM, Sun Z, Ky B, Upshaw J, et al
    A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
    Oncologist. 2021;26:523-532.
    PubMed     Abstract available
    
    
    May 2021
62. ALKREKSHI A, Tamaskar I
    Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
    Oncologist. 2021;26:e827-e830.
    PubMed     Abstract available
    
    
    
63. MIYAGAWA C, Takaya H, Sakai K, Nishio K, et al
    A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
    Oncologist. 2021;26:356-361.
    PubMed     Abstract available
    
    
    April 2021
64. KRUG K, Bossert J, Deis N, Krisam J, et al
    Effects of an interprofessional communication approach on support needs, quality of life and mood of advanced lung cancer patients: a randomized trial.
    Oncologist. 2021 Apr 16. doi: 10.1002/onco.13790.
    PubMed     Abstract available
    
    
    
65. PERAVALI M, Ahn J, Chen K, Rao S, et al
    Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small-Cell Lung Cancer.
    Oncologist. 2021 Apr 12. doi: 10.1002/onco.13787.
    PubMed     Abstract available
    
    
    
66. BERNICKER EH, Xiao Y, Abraham A, Yang B, et al
    Adherence to NCCN ALK testing guidelines for patients with advanced non-small cell lung cancer in US Community Medical Centers.
    Oncologist. 2021 Apr 6. doi: 10.1002/onco.13779.
    PubMed     Abstract available
    
    
    
67. JELINEK MJ, Aggarwal C
    Adjuvant Osimertinib: A New Standard of Care.
    Oncologist. 2021;26:263-265.
    PubMed    
    
    
    
68. VAN BRUMMELEN EMJ, Huijberts S, van Herpen C, Desar I, et al
    Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
    Oncologist. 2021;26:290-e545.
    PubMed     Abstract available
    
    
    
69. JIAO XD, Liu K, Xu M, Yu G, et al
    Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis.
    Oncologist. 2021;26:e524-e529.
    PubMed     Abstract available
    
    
    March 2021
70. ROSS JS, Sokol ES, Moch H, Mileshkin L, et al
    Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Oncologist. 2021;26:e394-e402.
    PubMed     Abstract available
    
    
    
71. WANG Y, Chen Z, Han X, Li J, et al
    Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Oncologist. 2021;26:178-181.
    PubMed     Abstract available
    
    
    January 2021
72. DURBIN SM, Zubiri L, Niemierko A, Bardia A, et al
    Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
    Oncologist. 2021;26:49-55.
    PubMed     Abstract available
    
    
    
73. CADRANEL J, Liu SV, Duruisseaux M, Branden E, et al
    Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
    Oncologist. 2021;26:7-16.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: